Press release

Cerenis Therapeutics admitted to the SRD (Defered Settlement Service) "Long-only"

Toulouse, FRANCE, Ann Arbor, UNITED-STATES, December 17, 2015 – **Cerenis Therapeutics (FR0012616852-CEREN),** an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies ("good cholesterol") for treating cardiovascular and metabolic diseases, announces that its shares will be admitted to the Euronext Paris SRD (*Service de Règlement Différé*, i.e. Deferred Settlement Service) from 29 December 2015, on the "*Long-seulement*" (Long-only) segment.

With a minimum daily trading volume of €100,000 over the past year, a condition for being admitted to the *SRD "Long-seulement"* (Long-only Deferred Settlement Service), the liquidity of Cerenis Therapeutics shares has increased significantly as a result of regular communications on its clinical development program.

In practical terms, the *SRD "Long-seulement"* will allow holders of a French securities account to purchase Cerenis Therapeutics shares on margin using the leveraged effect of deferred settlement. For the buyer, risks are thus limited to the initial size of the investment.

Being admitted to the *SRD "Long-seulement"* will make Cerenis Therapeutics shares more attractive and will increase liquidity by providing access to a broader base of institutional and individual investors.

About Cerenis Therapeutics: www.cerenis.com

Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body.

Cerenis is developing a portfolio of HDL therapies, including HDL-mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as post-ACS patients and patients with HDL deficiency, and drugs which increase HDL for patients with low number of HDL particles to treat atherosclerosis and associated metabolic diseases.

Cerenis is well-positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs being developed.

Since its inception in 2005, the company has been funded by top tier investors: Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, Daiwa Corporate Investment, TVM Capital, Orbimed, IRDI/IXO Private Equity and Bpifrance (Fund for Strategic Investment) and last March successfully completed an IPO on Euronext raising €53.4m.

About CER-001:

CER-001 is an engineered complex of recombinant human apoA-I, the major structural protein of HDL, and phospholipids. It has been designed to mimic the structure and function of natural, nascent HDL, also known as pre-beta HDL. Its mechanism of action is to increase apoA-I and the number of HDL particles transiently, to stimulate the removal of excess cholesterol and other lipids from tissues including the arterial wall and to transport them to the liver for elimination through a process called Reverse Lipid Transport. Previous Phase II studies have provided important data demonstrating the efficacy of CER-001 in regressing atherosclerosis in several distinct vascular beds in patients representing the entire spectrum of cholesterol homeostasis. The totality of the data to date indicates that CER-001 performs all of the functions of natural pre-beta HDL particles and has the potential to be the best-in-class HDL mimetic in the market.

CEREN LISTED EURONEXT — ELIGIBLE PEA PME

Contacts:

Cerenis
Jean-Louis Dasseux
CEO
info@cerenis.com
Tel: +33 (0)5 62 24 09 49

NewCap
Investors relations
Emmanuel Huynh / Louis-Victor Delouvrier
cerenis@newcap.eu
Tel: +33 (0)1 44 71 98 53

NewCap
Media relations
Nicolas Merigeau
cerenis@newcap.eu
Tel: +33 (0)1 44 71 94 98